Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor
Journal of Veterinary Internal Medicine · 04.05.2026 · 40 (3)
DOI: 10.1093/jvimsj/aalag098 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 05.06.2026. Verfasst von Esther Chon und 14 weiteren Autor:innen. Beteiligte Einrichtung: Merck Animal Health, Rahway, NJ, United States. Hauptthemen laut MEDLINE: Dog Diseases, Immune Checkpoint Inhibitors, Mastocytoma, Melanoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Animal Health.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) have transformed oncology in human medicine, providing clinical benefit in a broad spectrum of cancers. Widely available ICIs for dogs are lacking. Hypothesis/Objectives Evaluate efficacy and safety of gilvetmab, a caninized anti-PD-1 monoclonal antibody. Animals Fifty-one client-owned dogs were evaluated, 25 with stages II-III melanoma and 26 with stages I-III mast cell tumor (MCT). Fifteen dogs with stages III-V lymphoma were also evaluated.
Methods
Multi-institutional, open-label study. Enrolled dogs were treated with gilvetmab IV at 6 mg/kg q28d or 10 mg/kg q14d; 8 dogs receiving the lower dosage underwent dose escalation with their owners’ consent. Safety was evaluated by physical examinations, laboratory testing, and clinical observations made by veterinarians or the dogs’ owners. Efficacy was assessed by objective response rate (ORR) and time to progression (TTP) using cRECIST v1.0 and lymphoma response criteria.
Results
For melanoma, the ORR was 20% (95% confidence interval [CI], 7%-41%) and median TTP was 56 days. For MCT, the ORR was 46% (95% CI, 27%-67%) and median TTP was not reached. No objective responses were observed in dogs with lymphoma. Serious adverse events of anaphylaxis, hypotension, or tumor hemorrhage occurred in 3 dogs (3/51, 5.9%). Tumor enlargement before regression, consistent with possible pseudoprogression, was observed in 2 dogs with melanoma. Conclusions and clinical importance Gilvetmab has a reasonable expectation of efficacy and an acceptable preliminary safety profile in dogs with MCT stages I-III and melanoma stages II and III.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Merck Animal Health, Rahway, NJ, United States.
- Oradell Animal Hospital, Paramus, NJ, United States.
- VCA Katonah Bedford Veterinary Center, Bedford Hills, NY, United States.
- VCA Clinical Studies, Los Angeles, CA, United States.
- Las Vegas Veterinary Specialty Center, Las Vegas, NV, United States.
- BluePearl Pet Hospital Malvern, Malvern, PA, United States.
Förderung
- Merck Animal Health
Zitieren
APA
Chon, E., Morsey, M., Katz, T., Yamada, K., Bailey, D., Bergman, P. J., Burr, H., Clifford, C. A., Heeb, H., Manley, C., Phillips, B., Post, G., Vail, D. M., Rusk, A., & Stock, M. L. (2026). Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor. Journal of Veterinary Internal Medicine, 40(3). https://doi.org/10.1093/jvimsj/aalag098
Vancouver
Chon E, Morsey M, Katz T, Yamada K, Bailey D, Bergman PJ, et al. Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor. Journal of Veterinary Internal Medicine. 2026;40(3). doi:10.1093/jvimsj/aalag098
BibTeX
@article{Chon2026,
author = {Chon, Esther and Morsey, Mohamad and Katz, Terry and Yamada, Kazumi and Bailey, Dennis and Bergman, Philip J and Burr, Holly and Clifford, Craig A and Heeb, Heather and Manley, Christina and Phillips, Brenda and Post, Gerald and Vail, David M and Rusk, Anthony and Stock, Matthew L},
title = {Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor},
journal = {Journal of Veterinary Internal Medicine},
year = {2026},
volume = {40},
number = {3},
doi = {10.1093/jvimsj/aalag098}
}
EUVIMED